Interview with Dr. Emily L. Belleau and Dr. Sage E. Hawn
Considered by many to be the “father of psychopharmacology,” Dr. Donald F. Klein was a pioneer in the field of psychiatry. In honor of his legacy, the Anxiety and Depression Association of America (ADAA) recognizes the work of early career investigators through the Donald F. Klein Award. This year, Dr. Emily L. Belleau will be honored for her research on neurobiological markers associated with depression.
The Importance of the Klein Award
ADAA had the opportunity to speak with both Dr. Belleau and Dr. Sage E. Hawn, the 2022 Klein Award winner, about the significance of the award and their research. Both clinicians emphasized the importance of being recognized by ADAA and the networking opportunities that come with it.
Dr. Hawn’s Research on PTSD
Dr. Hawn’s winning research involved studying a gene that influences inflammatory processes and its relation to post-traumatic stress disorder (PTSD). As an advocate for open science, Dr. Klein strongly supported the sharing of research, which ADAA honors through the Klein Award.
Dr. Belleau’s Perspective on the Award
Dr. Belleau, a former participant in ADAA’s Alies Muskin Career Development Leadership Program, expressed her gratitude for the award and its impact on her early career. She emphasized the importance of diverse perspectives in moving the science forward and continues to engage in ADAA programs and events.
The Legacy of Dr. Klein
Dr. Klein’s research into depression, anxiety, and related disorders revolutionized how mental health professionals incorporate biology, genetics, and neuroscience into practice. His work galvanized the understanding of mental health disorders in a more inclusive way and earned him the 2005 ADAA Lifetime Achievement Award.